SCP0153
GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human)
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C184H273N51O57
Molekulargewicht:
4111.44
UNSPSC-Code:
12352200
NACRES:
NA.32
Empfohlene Produkte
Assay
≥95% (HPLC)
Form
lyophilized
Zusammensetzung
Peptide Content, ≥75%
Lagerbedingungen
protect from light
Lagertemp.
−20°C
Amino Acid Sequence
His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
Anwendung
GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human) has been used to study its effect on vascular endothelial growth factor-A (VEGFA)-mediated endothelium-dependent signaling and vasodilation.
Glycogen-like peptide-1 (GLP-1) is an amino acid peptide derived from proglucogon. GLP-1 is involved in the regulation of the glycemic index via its affect on glucagon and insulin levels. GLP-1 may be used to study its interaction with its receptor, the GLP-1 receptor.
Biochem./physiol. Wirkung
Glycogen-like peptide-1 (GLP-1) is an insulinotropic hormone, which takes part in increasing insulin secretion and insulin sensitivity. It also inhibits the secretion of glycogen and reduces fasting glucose levels.
Lagerklassenschlüssel
11 - Combustible Solids
WGK
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Voglibose: an alpha-glucosidase inhibitor
Dabhi AS, et al.
Journal of Clinical and Diagnostic Research : JCDR, 7(12), 3023-3023 (2013)
GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries
Egholm C, et al.
American Journal of Physiology. Heart and Circulatory Physiology, 311(5), H1214-H1224 (2016)
Alaa Al Helaili et al.
Biochemical and biophysical research communications, 533(1), 110-117 (2020-09-19)
Dysfunction of the gut-brain axis is one of the potential contributors to the pathophysiology of obesity and is therefore a potential target for treatment. Vagal afferents innervating the gut play an important role in controlling energy homeostasis. There is an
Fan Xiao et al.
Frontiers in cardiovascular medicine, 8, 709741-709741 (2021-09-14)
Objectives: This study explores the concentration and role of glucagon-like peptide-1 (GLP-1) in calcific aortic valve disease (CAVD). Background: Calcific aortic valve disease is a chronic disease presenting with aortic valve degeneration and mineralization. We hypothesized that the level of
Cecilie Egholm et al.
American journal of physiology. Heart and circulatory physiology, 311(5), H1214-H1224 (2016-11-03)
We investigated the acute effects of glucagon-like peptide-1 (GLP-1), GLP-1(1-36), and GLP-1(7-36) on vascular endothelial growth factor-A (VEGFA)-induced endothelium-dependent signaling and vasodilation. Our hypothesis was that GLP-1 released from intestinal l-cells modulates processes related to PLCγ activation, Src, and endothelial
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.